Items where authors include "Earl, H."

Article

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. ISSN 1470-2045

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045

Baird, R., Banks, I., Cameron, D. et al. (53 more authors) (2016) An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 10. p. 608.

Pirie, A., Guo, Q., Kraft, P. et al. (146 more authors) (2015) Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17. 58. ISSN 1465-5411